The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor.
The gamma-aminobutyric acid, type B (GABA(B)) receptor is well recognized as being composed of two subunits, GABA(B1) and GABA(B2). Both subunits share structural homology with other class-III G-protein-coupled receptors. They are composed of two main domains: a heptahelical domain (HD) typical of all G-protein-coupled receptors and a large extracellular domain (ECD). Although GABA(B1) binds GABA, GABA(B2) is required for GABA(B1) to reach the cell surface. However, it is still not demonstrated whether the association of these two subunits is always required for function in the brain. Indeed, GABA(B2) plays a major role in the coupling of the heteromer to G-proteins, such that it is possible that GABA(B2) can transmit a signal in the absence of GABA(B1). Today only ligands interacting with GABA(B1) ECD have been identified. Thus, the compounds acting exclusively on the GABA(B2) subunit will be helpful in analyzing the specific role of this subunit in the brain. Here, we explored the mechanism of action of CGP7930, a compound described as a positive allosteric regulator of the GABA(B) receptor. We showed that it activates the wild type GABA(B) receptor but with a low efficacy. The GABA(B2) HD is necessary for this effect, although one cannot exclude that CGP7930 could also bind to GABA(B1). Of interest, CGP7930 could activate GABA(B2) expressed alone and is the first described agonist of GABA(B2). Finally, we show that CGP7930 retains its agonist activity on a GABA(B2) subunit deleted of its ECD. This demonstrates that the HD of GABA(B2) behaves similar to a rhodopsin-like receptor, because it can reach the cell surface alone, can couple to G-protein, and be activated by agonists. These data open new strategies for studying the mechanism of activation of GABA(B) receptor and examine any possible role of homomeric GABA(B2) receptors.
Binet
Virginie
V
Department of Molecular Pharmacology, CNRS UPR2580, Centre CNRS-INSERM de Pharmacologie et Endocrinologie, Montpellier 34094 cedex 5, France.
Brajon
Carole
C
Le Corre
Laurent
L
Acher
Francine
F
Pin
Jean-Philippe
JP
Prézeau
Laurent
L
D000494:Allosteric Regulation; D000818:Animals; D002460:Cell Line; D019281:Dimerization; D004305:Dose-Response Relationship, Drug; D058786:GABA-B Receptor Agonists; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D007295:Inositol Phosphates / Q000378:metabolism; D008024:Ligands; D016297:Mutagenesis, Site-Directed; D010636:Phenols / Q000378:metabolism*; D017434:Protein Structure, Tertiary; D021122:Protein Subunits / Q000819:agonists / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D018080:Receptors, GABA-B / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
C438607:2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol; D058786:GABA-B Receptor Agonists; D007295:Inositol Phosphates; D008024:Ligands; D010636:Phenols; D021122:Protein Subunits; D018080:Receptors, GABA-B; D005680:gamma-Aminobutyric Acid; D019204:GTP-Binding Proteins